iScience. 2021 Aug 8;24(9):102961. doi: 10.1016/j.isci.2021.102961. eCollection 2021 Sep 24.
Pablo Ávalos Prado 1 2 3, Arnaud Landra-Willm 1 2 3, Clément Verkest 1 2 3 4, Aurore Ribera 1 2 3, Anne-Amandine Chassot 1 2 3, Anne Baron 2 3 4, Guillaume Sandoz 1 2 3
1 Université Côte d’Azur, CNRS, INSERM, iBV, Nice, France.
2 Laboratories of Excellence, Ion Channel Science and Therapeutics, Nice, France.
3 Fédération Hospitalo-Universitaire InovPain, Cote d’Azur University, University Hospital Centre Nice, Nice, Provence-Alpes-Côte d’Azur, France.
4 Universite Côte d’Azur, CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France.
Activation and sensitization of trigeminal ganglia (TG) sensory neurons, leading to the release of pro-inflammatory peptides such as calcitonin gene-related peptide (CGRP), are likely a key component in migraine-related headache induction. Reducing TG neuron excitability represents therefore an attractive alternative strategy to relieve migraine pain. Here by using pharmacology and genetic invalidation ex vivo and in vivo, we demonstrate that activating TREK1 and TREK2 two-pore-domain potassium (K2P) channels inhibits TG neuronal firing sufficiently to fully reverse the migraine-like phenotype induced by NO-donors in rodents. Finally, targeting TREK is as efficient as treatment with CGRP antagonists, which represents one of the most effective migraine therapies. Altogether, our results demonstrate that inhibiting TG excitability by pharmacological activation of TREK channels should be considered as an alternative to the current migraine treatment.